Penumbra (PEN) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Penumbra (NYSE: PEN):

• 8/2/2025 – Penumbra was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating.
• 7/31/2025 – Penumbra had its price target raised by analysts at Morgan Stanley from $260.00 to $266.00. They now have an “equal weight” rating on the stock.
• 7/30/2025 – Penumbra had its price target lowered by analysts at Wells Fargo & Company from $315.00 to $290.00. They now have an “overweight” rating on the stock.
• 7/30/2025 – Penumbra had its price target lowered by analysts at Royal Bank Of Canada from $330.00 to $325.00. They now have an “outperform” rating on the stock.
• 7/30/2025 – Penumbra had its price target raised by analysts at Robert W. Baird from $283.00 to $285.00. They now have an “outperform” rating on the stock.
• 7/30/2025 – Penumbra was given a new $310.00 price target on by analysts at Truist Financial Corporation. They now have a “buy” rating on the stock.
• 7/30/2025 – Penumbra was given a new $335.00 price target on by analysts at UBS Group AG. They now have a “buy” rating on the stock.
• 7/30/2025 – Penumbra was given a new $350.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 7/18/2025 – Penumbra was upgraded by analysts at William Blair to a “strong-buy” rating.
• 7/9/2025 – Penumbra had its price target lowered by analysts at Citigroup Inc. from $320.00 to $285.00. They now have a “neutral” rating on the stock.

Penumbra Stock Down 0.1%

PEN stock opened at $252.99 on Monday. Penumbra, Inc. has a fifty-two week low of $184.80 and a fifty-two week high of $310.00. The business’s 50 day moving average price is $246.04 and its two-hundred day moving average price is $265.56. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75. The company has a market capitalization of $9.87 billion, a price-to-earnings ratio of 67.28, a price-to-earnings-growth ratio of 2.28 and a beta of 0.40.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.05. The company had revenue of $339.46 million for the quarter, compared to the consensus estimate of $327.37 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%. The firm’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.64 EPS. As a group, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Arani Bose sold 12,000 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $250.65, for a total transaction of $3,007,800.00. Following the transaction, the director directly owned 558 shares of the company’s stock, valued at $139,862.70. This represents a 95.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam Elsesser sold 16,300 shares of the firm’s stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $267.91, for a total value of $4,366,933.00. Following the completion of the transaction, the chief executive officer directly owned 98,289 shares in the company, valued at approximately $26,332,605.99. This represents a 14.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 112,487 shares of company stock valued at $27,969,587. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Penumbra

Institutional investors have recently bought and sold shares of the business. Synergy Investment Management LLC purchased a new position in shares of Penumbra during the first quarter valued at about $27,000. First Horizon Advisors Inc. lifted its holdings in shares of Penumbra by 404.8% in the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock valued at $28,000 after acquiring an additional 85 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after acquiring an additional 66 shares during the last quarter. AlphaQuest LLC bought a new position in shares of Penumbra in the 1st quarter valued at about $66,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Penumbra by 209.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after acquiring an additional 184 shares during the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.